Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (80722)	5/16/2000 3:43:00 PM
From: Skeeter Bug	Read Replies (1) \| Respond to of 132070

mike, lgnd's annual product growth rate of 13% seems to... well... suck. am i missing something?

To: Knighty Tin who wrote (80722)	5/16/2000 9:53:00 PM
From: yard_man	Read Replies (1) \| Respond to of 132070

You <g>, but this is something that gives me real pause in investing in biotechs -- (besides no earnings for some of them and high cash burn rates). No doubt you'll make the point -- one ought to choose a diversified list of "good" companies. But how do you screen out the flops to get to a good list -- for some of the treatments, drugs, etc -- the contraindictions are everything. <ng> How do you personally decide -- are you tied into some folks in the medical community? Surely just reading the prospectuses isn't enough? Do you have rules about them being through a certain stage in the trials, etc.?